Physician profile
Daniel Smith
NPI 1235454901
$10,999.33
in general payments reported to CMS, 2019-2025
22 companies · $5,096 in 2025
The $5,096 reported for 2025 was more than what 93% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $299 · 2021: $456 · 2022: $1,255 · 2023: $436 · 2024: $2,799 · 2025: $5,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,555 · Travel and Lodging: $2,388 · Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,555.00 |
| Travel and Lodging | $2,387.62 |
| Food and Beverage | $2,387.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,318.41 | 2019-2025 | Na, Intracept, General - Pain Management |
| Surgentec | $3,759.36 | 2025 | Tilink |
| Painteq LLC | $863.63 | 2022 | |
| Abbvie INC. | $368.77 | 2024-2025 | |
| Nalu Medical, INC. | $295.48 | 2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $286.44 | 2021-2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Stryker Corporation | $234.51 | 2022 | |
| Nevro Corp. | $223.38 | 2019-2021 | |
| Abbott Laboratories | $112.38 | 2021-2025 | Eterna |
| Medtronic USA, INC. | $110.60 | 2019-2020 | |
| Relievant Medsystems, INC. | $94.41 | 2019 | |
| Saluda Medical Americas, INC. | $77.00 | 2024-2025 | Evoke |
| Stimwave Technologies Incorporated | $57.35 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.46 | 2019-2025 | Relistor |
| Si-Bone, INC. | $39.18 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.67 | 2025 | Bridion |
| Actelion Pharmaceuticals US, INC. | $19.16 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.27 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $13.89 | 2020 | |
| Lilly USA, LLC | $12.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 | |
| Biodelivery Sciences International, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.